Impact of Time Factors and Survival Outcomes of Hypofractionated Radiotherapy in Locally Advanced Head and Neck Cancers

Adeeb, Refka Y.; Abdel Latif, Wafaa M.; Guirguis, Amani S.; Abdel Fatah, Sherweif M.

doi:10.21608/mjmr.2024.332823.1826

	Impact of Time Factors and Survival Outcomes of Hypofractionated Radiotherapy in Locally Advanced Head and Neck Cancers
Minia Journal of Medical Research
Articles in Press, Accepted Manuscript, Available Online from 17 November 2024
Document Type: Original Article
DOI: 10.21608/mjmr.2024.332823.1826
View on SCiNiTO
Authors
Refka Y. Adeeb ¹; Wafaa M. Abdel Latif¹; Amani S. Guirguis¹; Sherweif M. Abdel Fatah²
¹Department of clinical oncology, Faculty of medicine, Minia university, Egypt.
²Department of radiation oncology , Faculty of medicine, Cairo university, Egypt.
Abstract
With results comparable to those of traditional fractionated radiation, hypofractionation has been reintroduced for numerous tumor locations as a result of radiotherapy's progress in the last several decades. Hypofractionation is not new, but it has only been utilized in a handful of countries to treat locally advanced head and neck cancer (LAHNC). Objective:Survival results for patients with locally advanced head and neck malignancies were examined in this experiment to determine the effect of time factors of hypofractionated radiation (HYP-RT) with concurrent cisplatin (CDDP). Methods: Fifty patients with nonmetastatic Stage III and IV cancers were included in the study, which began in January of 2021.The intensity-modulated radiation treatment the patients underwent included 54 Gy/18 fractions for the gross tumor and 48 Gy/18 fractions for the subclinical disease regions. The concurrent CDDP regimen was 35 mg/m2 administered weekly. Overall survival (OS), progression-free survival (PFS), and the effect of time variables (RTT, therapy start delay) were the main outcomes. Results:From January to December of 2021, fifty patients were enrolled, and they were tracked until April of 2024. The whole course of radiation treatment was finished by all patients.Overall, patients survived for an average of 19 months, with 9.5 months of progression-free survival being the median. OS and PFS are greatly impacted by the length of time it takes to begin treatment. Conclusion:Because the initial toxicity rate was similar to that of conventional concurrent chemoradiation,HYP-RT with CDDP was thought to be a viable option for LAHNC. Radiation treatment improves survival rates when started early.
Keywords
(LAHNC); (HYP-RT); (CDDP)


Statistics Article View: 66